Compound details
Itoside J
| Compound ID | CDAMM01641 |
|---|---|
| Common name | Itoside J | IUPAC name | [2-[6-(benzoyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxyphenyl]methyl 1-hydroxy-5-[[5-hydroxy-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methylidene]-6-oxocyclohex-2-ene-1-carboxylate |
| Molecular formula | C40H42O19 |
| Retention time | 6.46 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 827.232 | Theoretical mz | 827.239 |
| Error | 8.55 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 7.1317 |
| Inchi key | VJDJBHKKFHYOAP-PEFXGDRSNA-N |
|---|---|
| Smiles | O=C(OCC1OC(OC2=CC=C(O)C=C2COC(=O)C3(O)C=CCC(=CC4=CC(O)=CC=C4OC5OC(CO)C(O)C(O)C5O)C3=O)C(O)C(O)C1O)C=6C=CC=CC6 |
| Superclass | Organic oxygen compounds |
| Class | Organooxygen compounds |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P15692 | VEGFA | Vascular endothelial growth factor A | T20761 | SwissTargetPrediction and SEA |
| P05230 | FGF1 | Acidic fibroblast growth factor | T18639 | SwissTargetPrediction and SEA |
| P09038 | FGF2 | Basic fibroblast growth factor | T31621 | SwissTargetPrediction and SEA |
| Q9Y251 | HPSE | Heparanase | T47623 | SwissTargetPrediction |
| P16109 | SELP | P-selectin | T10965 | SEA |
| P60568 | IL2 | Interleukin-2 | T61698 | SEA |
| Q9NUW8 | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | T33492 | SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| P20916 | MAG | Myelin-associated glycoprotein (by homology) | T95286 | SEA |
| P09382 | LGALS1 | Galectin-1 | T09544 | SEA |
| Q9NZ08 | ERAP1 | Endoplasmic reticulum aminopeptidase 1 | T72849 | SEA |
| P30837 | ALDH1B1 | Acetaldehyde dehydrogenase | T99641 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T20761 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P15692 | VEGFA |
| T20761 | DI0365 | Retinopathy | [ICD-11: 9B71] | P15692 | VEGFA |
| T20761 | DI0430 | Vascular system developmental anomaly | [ICD-11: LA90] | P15692 | VEGFA |
| T18639 | DI0081 | Chronic arterial occlusive disease | [ICD-11: BD4Z] | P05230 | FGF1 |
| T18639 | DI0102 | Coronary atherosclerosis | [ICD-11: BA52] | P05230 | FGF1 |
| T31621 | DI0005 | Acne vulgaris | [ICD-11: ED80] | P09038 | FGF2 |
| T47623 | DI0020 | African trypanosomiasis | [ICD-11: 1F51] | Q9Y251 | HPSE |
| T47623 | DI0310 | Ocular disease | [ICD-11: N.A.] | Q9Y251 | HPSE |
| T10965 | DI0088 | Circulatory system disease | [ICD-11: BE2Z] | P16109 | SELP |
| T10965 | DI0381 | Sickle-cell disorder | [ICD-11: 3A51] | P16109 | SELP |
| T61698 | DI0275 | Multiple sclerosis | [ICD-11: 8A40] | P60568 | IL2 |
| T61698 | DI0361 | Renal cell carcinoma | [ICD-11: 2C90] | P60568 | IL2 |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |
| T95286 | DI0219 | Ischaemic/haemorrhagic stroke | [ICD-11: 8B20] | P20916 | MAG |
| T99641 | DI0396 | Substance abuse | [ICD-11: 6C40] | P30837 | ALDH1B1 |